Abstract

With Transcatheter Aortic Valve Replacement (TAVR) revolutionizing the treatment of high-surgical risk patients with severe aortic stenosis, Transcatheter Mitral Valve Replacement (TMVR) is slowly emerging as an off-label therapy for severe mitral valve disease. A case of 70-year-old female with recurrent history of congestive heart failure has been described. This case demonstrates the simultaneous TAVR and off-label VIV TMVR is a reasonable alternative for highrisk surgical patients with stenotic native and failing bioprosthetic valves.